A Phase 2a Study to Evaluate EDP-938 in the Virus Challenge Model

NCT03691623 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

179

Enrollment

INDUSTRY

Sponsor class

Conditions

RSV Infection

Interventions

DRUG: EDP-938 Dose 1
DRUG: EDP-938 Dose 2
DRUG: Placebo
DRUG: EDP-938 Dose 3
DRUG: EDP-938 Dose 4
DRUG: Placebo

Sponsor

Enanta Pharmaceuticals, Inc

Collaborators

[object Object]